TREATMENT OF END-STAGE PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS-CELL CARCINOMAS BY INTRALESIONAL APPLICATION OF HUMAN FIBROBLAST INTERFERON

STEUER, MK and MATTHIAS, R and SCHULZE, C and BRUSIS, T (1992) TREATMENT OF END-STAGE PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS-CELL CARCINOMAS BY INTRALESIONAL APPLICATION OF HUMAN FIBROBLAST INTERFERON. LARYNGO-RHINO-OTOLOGIE, 71 (12). pp. 618-625. ISSN 0935-8943,

Full text not available from this repository.

Abstract

It has been the aim of the present investigation to study the effect of intratumorally applied human fibroblast interferon (nIFN-beta; Fiblaferon(R)5 for the first two weeks, and Fiblaferon(R) 3 three times a week) in a phase-II clinical trial of thirteen patients with advanced head and neck squamous cell carcinomas. All of the patients had failed established therapeutic modalities before and could not be treated by conventional procedures. nIFN-beta was injected intratumorally and its effect on tumour size was assessed by an independent, second observer as well as via CT and MR imaging. All assessments were done prior to treatment, 8 weeks after beginning treatment and at 16 weeks. Three female and ten male patients with primary tumours of the hypopharynx (n = 5), the larynx (n = 4), the oropharynx (n = 1), the glandula submandibularis (n = 1), the oral cavity (n = 1) and the oesophagus (n = 1) have undergone outpatient treatment three times a week. Tumour size showed no change in six patients while progressive disease occurred in seven cases after eight weeks of treatment. Radiological findings did not change in the nine patients continuing treatment while five showed progressive disease. There were no serious local or systemic side effects due to the intratumoral nIFN-beta treatment. The survival time was 9.73 months after the onset of nIFN-beta treatment.

Item Type: Article
Uncontrolled Keywords: ; HEAD AND NECK; ADVANCED SQUAMOUS CELL CARCINOMAS; HUMAN FIBROBLAST INTERFERON; INTRALESIONAL APPLICATION
Depositing User: Dr. Gernot Deinzer
Last Modified: 19 Oct 2022 08:44
URI: https://pred.uni-regensburg.de/id/eprint/54270

Actions (login required)

View Item View Item